Introduction
Hepatic arterial infusion pump (HAIP) chemotherapy is a promising treatment for patients with unresectable intrahepatic cholangiocarcinoma (iCCA). This study compares perioperative outcomes of robotic versus open HAIP placement in these patients.
Study Design
This multicenter cohort study analyzed patients with unresectable iCCA from the PUMP-II trial (January 2020 to September 2022) at Amsterdam UMC, Erasmus MC, and UMC Utrecht. The primary outcome was time to functional recovery (TTFR). Secondary outcomes included length of hospital stay, postoperative complications, and time to start HAIP chemotherapy.
Results
TTFR: Median of 2 days for robotic HAIP placement vs. 5 days for open HAIP placement (p < 0.001).
Length of Hospital Stay: 3 days for robotic vs. 6 days for open (p < 0.001).
Postoperative Complications: Comparable between groups (36% for robotic, 39% for open).
HAIP Chemotherapy Initiation: All patients in the robotic group vs. 93% in the open group (p = 0.497).
Time to Start HAIP Chemotherapy: Median of 14 days for robotic vs. 18 days for open (p = 0.153).
Discussion
Robotic HAIP placement resulted in significantly shorter TTFR and hospital stays compared to open HAIP placement, with similar safety profiles. The robotic approach offers an effective alternative, potentially reducing recovery times and hospital resource utilization.
Conclusion
Robotic HAIP placement for unresectable iCCA is a safe, effective procedure that enhances recovery and reduces hospital stays. Surgeons should consider this approach to improve patient outcomes.
Read the full study: https://doi.org/10.1245/s10434-024-15127-w
Leave a Reply